Stellar Pharmaceuticals gets Uracyst patent in Japan

Stellar Pharmaceuticals (OTCQB:SLXCF) has received a patent from the Japan Patent Office for one of its lead products, Uracyst,  covering the treatment of cystitis and other related conditions by instillation into the bladder of a dose comprising of at least 350 mg in a volume of from 10 ml to 100 ml. The patent will [...]

Stellar allowed Uracyst patent in U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to its Uracyst treatment of interstitial cystitis/painful bladder syndrome.  The patent will expire in 2024. The issuance of the patent triggers a milestone payment of $1.3 million (U.S.) from Stellar’s U.S. marketing and distribution [...]

Stellar signs distributor for Uracyst in Germany and Austria

After tapping into the Portugal market earlier this week, Stellar Pharmaceuticals (OTCBB: SLXCF) signed a license agreement with medac GmbH for the distribution and sale of its Uracyst treatment for interstitial cystitis/painful bladder syndrome in Germany and Austria. “This agreement not only represents an important revenue opportunity for Stellar and medac, but also offers hope [...]

Stellar signs distributor for Uracyst in Portugal

Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for interstitial cystitis/painful bladder syndrome will be distributed in Portugal by CPH Companhia Portuguesa Higiene, a specialty pharma company with a major focus in urology, the primary target market for Uracyst. “Expanding the global licensing of Uracyst is a major growth driver for Stellar,” CEO, Peter Riehl, said in [...]